Discover how ACT-CHIK is being featured by international news outlets, scientific publications, and health media around the world.
The ACT-CHIK project has attracted international media attention for its efforts to accelerate the development of chikungunya vaccines in Africa. This page showcases independent news stories, press reports, and feature articles highlighting the project’s objectives, partnerships, and milestones.
June 2026
đź“° New Times Rwanda | 2026-06-10
A new multicountry initiative has been launched in Kigali to accelerate the development of a vaccine against Chikungunya …
đź“°Genetic Engineering & Biotechnology News |2026-06- 08
Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK
Institut Pasteur is launching ACT-CHIK (Accelerating Clinical Trials for CHIKungunya Vaccine in Africa), a four-year research project funded by the Global Health EDCTP3 Joint Undertaking under the European Union’s Horizon Europe program that aims to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa…
📰Caducée.net | 2026-06-08
Vaccin contre le chikungunya : pourquoi ACT-CHIK mise sur l’AfriqueÂ
CoordonnĂ© par l’Institut Pasteur, le projet ACT-CHIK veut accĂ©lĂ©rer le dĂ©veloppement clinique du candidat vaccin MV-CHIK contre le chikungunya, avec un essai de phase Ib/III menĂ© dans quatre pays africains…Â
đź“°La Gazette du Laboratoire | 2026-06-11
Un nouveau projet de 15,3 millions d’euros, financĂ© par le partenariat Global Health EDCTP3 et coordonnĂ© par l’Institut Pasteur, rassemble sept partenaires sur quatre continents. L’objectif : faire avancer les essais cliniques et prĂ©parer la fabrication d’un vaccin contre le chikungunya en Afrique…